Drug · CHEMBL786

TAMOXIFEN CITRATE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. TAMOXIFEN CITRATE. Drugs and targets, record CHEMBL786. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL786

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: TAMOXIFEN CITRATE; ChEMBL
ChEMBL ID: CHEMBL786; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Emblon, Fentamox 10, Fentamox 20, Kentadex, Kessar 10, Kessar 20, Noltam, Nolvadex, Nolvadex d, Nolvadex fte, Oestrifen-10, Oestrifen-20, Oestrifen-40, Soltamox, Tamofen, Zynoplex; ChEMBL
Other names: I.C.I.46474 CITRATE, ICI 46,474, ICI-46474, Kessar, NSC-180973, NSC-757345, Nourytam, Tamofene, Tamoxifeni citras, Tomaxasta, Zemide, Zitazonium; ChEMBL
Parent form: TAMOXIFEN, CHEMBL83; Drugs and targets
InChIKey: FQZYTYWMLGAPFJ-OQKDUQJOSA-N; ChEMBL
Open Targets' highest stage: Approval, for 1 of its 24 diseases, from DailyMed; Open Targets

Targets1

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
ESR1	Estrogen receptor	Estrogen receptor alpha modulator	MODULATOR	https://conductscience.org/library/genes/2099

Source ChEMBL

Diseases24

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
breast cancer	Approval	DailyMed	28	26	https://conductscience.org/library/drugs?q=MONDO_0007254
ductal breast carcinoma in situ	Phase 2	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0005023
endometrial cancer	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0011962
adrenal gland cancer	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0002817
adrenal gland neoplasm	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0021227
brain neoplasm	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0021211
brain stem glioma	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0002911
breast adenocarcinoma	Phase 3	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0004988
cystic fibrosis	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0009061
endometrial carcinoma	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0002447

1 to 10 of 24Source Open Targets

See all 24 diseases

Trials45

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01272037	Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer	Phase 3	5,018	2023-06-27	tamoxifen citrate	Its name	ClinicalTrials.gov
NCT01674140	S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer	Phase 3	1,939	2023-12-20	tamoxifen citrate	Its name	ClinicalTrials.gov
NCT00601900	Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer	Phase 3	394	2016-08-23	tamoxifen citrate	Its name	ClinicalTrials.gov
NCT00041080	Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Phase 3	139	2013-09-16	tamoxifen citrate	Its name	ClinicalTrials.gov
NCT02993159	Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast	Phase 2	100	2024-12-18	tamoxifen citrate	Its name	ClinicalTrials.gov
NCT00290745	Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ	Phase 1/2	79	2020-12-04	tamoxifen citrate	Its name	ClinicalTrials.gov
NCT00729586	Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	Phase 2	73	2018-08-27	tamoxifen citrate	Its name	ClinicalTrials.gov
NCT01293032	Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer		59	2016-07-12	tamoxifen citrate	Its name	ClinicalTrials.gov
NCT00003042	Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer	Phase 2	41	2021-04-08	tamoxifen citrate	Its name	ClinicalTrials.gov
NCT04129216	The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer	Phase 2	30	2024-05-07	tamoxifen citrate	Its name	ClinicalTrials.gov

1 to 10 of 45

See all 45 trials

Comparisons in its trials14

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Chemo and Endocrine Therapy vs Endocrine Therapy Alone: deaths from any cause	161 of 2,487	175 of 2,497	4,984	NCT01272037	Trial comparisons
Chemo and Endocrine Therapy vs Endocrine Therapy Alone: serious adverse events	14 of 2,062	9 of 2,342	4,404	NCT01272037	Trial comparisons
Everolimus vs Placebo: deaths from any cause	112 of 896	119 of 896	1,792	NCT01674140	Trial comparisons
Everolimus vs Placebo: serious adverse events	180 of 874	77 of 881	1,755	NCT01674140	Trial comparisons
Arm I (Endocrine Therapy With Monoclonal Antibody) vs Arm II (Endocrine Therapy): serious adverse events	56 of 195	30 of 196	391	NCT00601900	Trial comparisons
Grp - 1 vs Grp - 2: serious adverse events	3 of 67	1 of 69	136	NCT00041080	Trial comparisons
Arm I (4-OHT Topical Gel, Placebo) vs Arm II (Placebo, Oral Tamoxifen): deaths from any cause	0 of 47	0 of 53	100	NCT02993159	Trial comparisons
Arm I (4-OHT Topical Gel, Placebo) vs Arm II (Placebo, Oral Tamoxifen): serious adverse events	0 of 47	0 of 53	100	NCT02993159	Trial comparisons
Arm 1: Temsirolimus vs Arm 2: Megestrol Acetate+Tamoxifen+ Temsirolimus: Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events Version 3.0	29 of 50	15 of 21	71	NCT00729586	Trial comparisons
Arm 1: Temsirolimus vs Arm 2: Megestrol Acetate+Tamoxifen+ Temsirolimus: deaths from any cause	33 of 50	16 of 21	71	NCT00729586	Trial comparisons

1 to 10 of 14

See all 14 comparisons in its trials

Papers from its trials37

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
18952561	RESULT	1	PubMed
16344321	RESULT	1	PubMed
42458791	DERIVED	1	PubMed
41379459	DERIVED	1	PubMed
39656951	DERIVED	1	PubMed
39621968	DERIVED	1	PubMed
39191270	DERIVED	1	PubMed
38833643	DERIVED	1	PubMed
37870954	DERIVED	1	PubMed
37748109	DERIVED	1	PubMed

1 to 10 of 37

See all 37 papers from its trials

Tests in its trials1

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome
Verbal Learning	1	1

Source ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL786

GET https://conductscience.org/api/drugs/v1/CHEMBL786/diseases?page=2

API reference For AI assistants